Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
Clinical Pharmacology in Drug Development|May 11, 2016
Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy SubjectsHerbert Struemper, Thomas Murtaugh, Jane Gilbert, et al.Clinical Pharmacokinetics|May 30, 2025
Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple MyelomaTheodoros Papathanasiou, Josh Kaullen, Kishore Polireddy, et al.Journal of Clinical Pharmacology|January 21, 2014
Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritisHerbert Struemper, Mark Sale, Bela R Patel, et al.CPT: Pharmacometrics & Systems Pharmacology|February 22, 2025
Development of a Joint Tumor Size-Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision-MakingHerbert Struemper, Chetan Rathi, Morris Muliaditan, et al.CPT: Pharmacometrics & Systems Pharmacology|February 22, 2025
Tutorial on Conditional Simulations With a Tumor Size-Overall Survival Model to Support Oncology Drug DevelopmentSebastiaan C Goulooze, Morris Muliaditan, Richard C Franzese, et al.Cancer Immunology Research|April 30, 2014
Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation studyFiona Simpkins, Aurea Flores, Christina Chu, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 27, 2013
A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphomaMichael J Robertson, Justin Kline, Herbert Struemper, et al.Journal of Pharmacokinetics and Pharmacodynamics|February 4, 2016
Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working GroupPeter L Bonate, Malidi Ahamadi, Nageshwar Budha, et al.Clinical and Translational Science|September 13, 2022
Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog developmentNeeltje Steeghs, Aaron R Hansen, Glenn J Hanna, et al.Clinical Pharmacology and Therapeutics|June 23, 2020
Opportunities for Quantitative Translational Modeling in OncologyJames W T Yates, Helen Byrne, Sonya C Chapman, et al.Pageof 3